Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the Aurora-B Kinase Inhibitor barasertib-hQPA

Figure 2

Specificity of barasertib-hQPA in AML cell lines. A(i), B(i) Effect of 24 hours barasertib-hQPA exposure on pHH3 expression in leukaemic cell lines (*p = 0.001/**p = 0.003/***p = 0.207) (analysed using paired samples t-test), +95% confidence interval). A(ii), B(ii) Effect of 72 hours barasertib-hQPA exposure on viable cell count in leukaemic cell lines measured using 7AAD and fixed stained cells. Columns/lines, mean of three experiments; bars, SD.

Back to article page